Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents

Area of Science:

• Oncology
• Pharmacology
• Epigenetics

Background:

• Histone Deacetylase (HDAC) inhibitors represent a novel class of anti-cancer therapeutics.
• These agents modulate epigenetic and non-epigenetic pathways, inducing apoptosis and cell cycle arrest in cancer cells.
• Four HDAC inhibitors (vorinostat, romidepsin, belinostat, panobinostat) are FDA-approved for specific hematological malignancies.

Purpose of the Study:

• To review major structural classes of HDAC inhibitors currently in clinical trials.
• To discuss the role of molecular modeling in the rational design of novel HDAC inhibitors.
• To guide the discovery of HDAC inhibitors with enhanced therapeutic efficacy.

Main Methods:

• Literature review of HDAC inhibitors in clinical development.
• Analysis of four major structural classes: hydroxamic acid derivatives, aminobenzamide, cyclic peptides, and short-chain fatty acids.
• Exploration of computer modeling tools for structural modification and drug design.

Main Results:

• Identified four key structural classes of HDAC inhibitors in clinical trials.
• Highlighted the utility of molecular modeling in guiding the development of new HDAC inhibitors.
• Emphasized ongoing clinical trials for various hematological malignancies and solid tumors.

Conclusions:

• HDAC inhibitors show significant therapeutic potential in cancer treatment.
• Rational drug design, particularly molecular modeling, is crucial for discovering more effective HDAC inhibitors.
• Continued research and clinical evaluation are essential for expanding the application of HDAC inhibitors.